Business Insider

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment ...

This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and procurement of Ebanga™, with a maximum value of $704 million Program progress and performance ...
Business Insider

Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness

GAITHERSBURG, Md., June 03, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response ...
Nasdaq

Emergent BioSolutions Awarded $62.4 Million Contract Modification for BAT® Antitoxin by U.S. Department of Health and Human Services

Emergent BioSolutions receives a $62.4 million contract modification to supply Botulism Antitoxin for U.S. public health protection. Emergent BioSolutions Inc. announced the award of a $62.4 million ...
Nasdaq

Emergent BioSolutions Secures Contract Modification for Additional VIGIV Doses to Support U.S. Smallpox Preparedness

Emergent BioSolutions Inc. announced a contract modification with the U.S. Department of Health and Human Services to provide additional doses of its smallpox treatment, CNJ-016® (Vaccinia Immune ...
Seeking Alpha

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense ...

GAITHERSBURG, Md., July 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016 ® [Vaccinia Immune Globulin ...
Seeking Alpha

Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

GAITHERSBURG, Md., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration ...
Becker's Hospital Review

J&J, Emergent BioSolutions to end vaccine supply contract

Johnson & Johnson and Emergent BioSolutions pointed blame at each other June 6 for breaking agreements in a COVID-19 vaccine supply contract, according to the Wall Street Journal. Emergent ...
Morningstar

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance ...

About Emergent BioSolutions At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective ...
Morningstar

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

About Emergent BioSolutions At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective ...
Eagle-Tribune

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin ...

GAITHERSBURG, Md., June 23, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a $62.4 million contract modification from the Administration for ...